PET-CT outcomes from a randomised controlled trial of rosuvastatin as an adjunct to standard tuberculosis treatment

PET-CT outcomes from a randomised controlled trial of rosuvastatin as an adjunct to standard tuberculosis treatment

Abstract Adjunctive rosuvastatin for rifampicin-susceptible pulmonary tuberculosis (rs-PTB) shows no effect on microbiological or radiological outcomes in a phase IIb randomised, controlled trial (NCT04504851). We explore the impact of adjunctive rosuvastatin on 18F-fluorodeoxyglucose (FDG) positron...

Full description

Saved in:
Bibliographic Details
Main Authors: Gail B. Cross, Intan P. Sari, Sarah M. Burkill, Chee Woei Yap, Han Nguyen, Do Quyet, Victoria B. Dalay, Emmanuel Gutierrez, Vincent M. Balanag, Randy J. Castillo, Christina C. Chang, Anthony D. Kelleher, Jim O’Doherty, Nicholas I. Paton
Format: Article
Language:English
Published: Nature Portfolio 2024-12-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-54419-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-024-54419-3

Similar Items